下一代抗体：免疫肿瘤学的新时代_New Era in Immuno-Oncology - August 2025.pptxVIP

Next-Generation

Antibodies:ANewErainImmuno-Oncology

Theopportunityisreal–butonlyforthosewhomovefastandoutpacethecompetition

August2025

Theimmunecheckpointinhibitor(ICI)patentcliffsetsthestagefortransformativeinnovationandgrowthinsolidtumors

Earlymoverswithsharpclinicalstrategiesorwinningcombinationswilllead

Bispecificsandbeyond:thenextwaveofinnovation

RecentsetbacksinnovelICItargetsareshiftingfocustowardnext-genantibodyplatformswheremomentumis

accelerating:

•Anti-PD(L)1/VEGFbispecificsare

gainingtraction,withawaveofdealsin2024andPfizerentryin2025

•EmergingmodalitiesincludingADC-IOcombinations,trispecifics,and

anti-TGFβaredrawinginvestment

A$50Bopeningin

immuno-oncology(IO)

Toexpandthemarket,newIO

therapiesforsolidtumorsmustgobeyondthelimitsoflegacyICIsby:

•Improvingoverallsurvival

•Expandingcoverageacrosstumortypesandlinesoftherapy

•Overcomingresistance

Theraceison,andtheclockisticking

Thenext24-36monthsarecritical,andsuccesswilldependon:

•Targetinghigh-valueniches

•Designingfast,adaptivetrials

•Buildingclearlydifferentiatedproducts

2

Company

Brand(drug)

Mechanismofaction

2023Revenue

ProjectedLOE(US)

Keytruda

(pembrolizumab)

anti-PD1

$25.0B

2028

Opdivo

(nivolumab)

anti-PD1

$10.0B

2028

Imfinzi

(durvalumab)

anti-PDL1

$4.72B

2031

Tecentriq

(atezolizumab)

anti-PDL1

$4.19B

2028

Yervoy

(ipilimumab)

anti-CTLA4

$2.24B

2025

Bavencio

(avelumab)

anti-PDL1

$771M

2030

~$50Btotal

Theupcoming~$50BpatentcliffinIOrepresentsoneofthe

decade’smostsignificantopportunitiesforRD-drivengrowth

ICIdrugsfacinglossofexclusivityoverthenext6years

Theraceison:WhichemergingIOtherapiescouldchallengeKeytruda’sdominanceinsolidtumors?

Source:GlobalData;non-exhaustive;Note:Logosshownareforillustrativepurposesonly.Alltrademarksandbrandlogos